Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3386 - Characteristics of the psychosomatic state of patients with lung cancer

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Galina Zhukova

Citation

Annals of Oncology (2018) 29 (suppl_8): viii557-viii561. 10.1093/annonc/mdy296

Authors

G. Zhukova1, A.I. Shikhlyarova1, E. Shirnina2, M. Zinkovich3, N. Maschenko4, E. Zlatnik3, S. Pyltsin4, P. Anistratov3, M.I. Bragina1, A. Zhadobina4, L.Y. Vladimirova5

Author affiliations

  • 1 Testing Laboratory Center, Rostov Research Oncology Institute, 344037 - Rostov-on-Don/RU
  • 2 Testing Laboratory Center, Rostov Research Oncology Institute, Rostov-on-Don/RU
  • 3 Medical Oncology, Rostov Research Oncology Institute, 344037 - Rostov-on-Don/RU
  • 4 Testing Laboratory Center, Rostov Research Oncology Institute, 344 - Rostov-on-Don/RU
  • 5 Medical Department, Rostov Research Institute of Oncology, 344037 - Rostov-on-Don/RU

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3386

Background

The important issue of psychophysiological adaptation to malignant process is poorly studied. The aim of the research was to elucidate characteristics of the psychic, adaptive and hormonal status of patients with lung cancer (LC).

Methods

Studies were performed in 28 LC patients with receiving surgery and chemoradiotherapy. The patients were divided into 3 groups: 1 - unresectable tumors, 2 - resectable tumors with metastases, 3 - resectable tumors without detected metastases. Personal (PA) and situational anxiety (SA) (Spielberger-Khanin test), depression (Zung test), the types of the mental response to disease (LOBI, Bechterew Institute Personality Inventory) were evaluated. With the help of blood count and the original computer program "Antistress", we calculated the quantitative indicator (QI) of the general nonspecific adaptation reactions of the body (AR) (Garkavi L. H. et al., 1975). Hormone levels of thyroid and pituitary-adrenal (PAS) systems in the blood were determined by electrochemiluminescent method (Cobase 411E).

Results

The studied groups did not differ in PA and SA. The signs of tension of the PAS, elevated thyroxine level and decline in the adaptive status were noted. At the same time, QI of AR in patients of the group 3 was 1.8-2.7 times higher than in patients of other groups (p < 0.05). Depression was observed in only one patient. The euphoric type of response to the disease dominated in the groups (39% of cases), the harmonic type was the second most frequent (18% of cases). The patients of group 3 with euphoric reaction (referred to non-rational types of response) were characterized by an uncomplicated postoperative period and the maximal QI of AR in the studied groups, which exceeded by 2 times the indices in the patients of group 3 with harmonic and other reactions (p < 0.01).

Conclusions

QI of AR of patients with LC reflected the prevalence of the malignant process. In these patients depression was not expressed, and the euphoric reaction dominated. That could be due to central effects of thyroxin. We assumed that the euphoric reaction in the patients with resectable LC without detected metastases was a favorable diagnostic characteristic. So the questions arise about the clarification of the concept of the euphoric reaction and the ways of its identification.

Clinical trial identification

Legal entity responsible for the study

Ministry of Health of the Russian Federation.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.